Mark Doerr

Mark Doerr is a principal and senior research analyst at Tech Insider covering medical technology companies with a focus on cardiovascular and related therapeutic technology. Mark leverages his prior experience as the director of marketing and business development at a medical device company, along with an extensive network of physician and industry relationships, to provide a unique perspective on the medtech sector. Prior to joining Tech Insider in 2011 he covered medical technology for four years at Craig-Hallum Capital, and has in total 20 years of financial and medtech industry experience.

Notable Analyst Updates – Spectranetics, HSBC, Verizon, New Home Company, Real Page

Sprectranetics (NASDAQ:SPNC) rose 10% and touched a 52-week high after the company said late Monday its trial using laser atherectomy to treat patients suffering from peripheral artery disease (PAD) had achieved statistical endpoints. Separately, Stifel Nicolas repeated its Buy recommendation on the stock and raised its price target to $30 from $24. Spectranetics, a maker…

Read More

NAB Posts Another Strong Quarter

National Australia Bank delivered another solid performance for first-quarter fiscal 2014 with a 7% increase in unaudited cash profit to AUD 1.55 billion, modestly below consensus of AUD 1.58 billion. Earnings for the major bank again benefited from a sharp fall in bad debts, down 23% to AUD 324 million for the quarter. Moderate loan…

Read More

Blount Conference Call Clarifies a Few Issues; 2014 Now Looks Like a Transition Year

On Monday, February 10, Blount issued a broad press release lowering its 2013 guidance and offering 2014 guidance that was below the Street expectations. Management held a conference call Tuesday afternoon to explain the results and outlook. Other corporate information was offered as well, including new 2018 targets and an update on the company’s long-term…

Read More